Zafgen to Present at the 31st Annual ROTH Conference Nasdaq:ZFGN

2019-03-13 05:25:19

(MENAFN- GlobeNewsWire - Nasdaq) itemprop="articleBody">BOSTON, March 13, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq: ZFGN ), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that Jeffrey Hatfield, Chief Executive Officer of Zafgen, Inc. will participate in a fireside discussion at the 31st Annual ROTH Conference on Tuesday, March 19, 2019 at 11:30 a.m. PT.

A live audio webcast and replay of the presentation will be available through the Events and Presentations page of the Investors section of the Company's website ( www.zafgen.com ) for 90 days following the conclusion of the live event.

About Zafgen

Zafgen (Nasdaq: ZFGN ) is a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for patients affected by complex metabolic diseases. Zafgen has pioneered the study of MetAP2 inhibitors in both common and rare metabolic disorders and is currently advancing programs for type 2 diabetes, Prader-Willi syndrome and liver diseases. Learn more at www.zafgen.com .

Media/Investor Relations Contacts:
Zafgen, Inc.
Patricia Allen
Chief Financial Officer
617-648-9792

Media
Krystle Gibbs
Ten Bridge Communications

508-479-6358

Investors
John Woolford
Westwicke

443-213-0506

MENAFN1303201900703653ID1098249749

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.